ZLAB — Zai Lab Ltd

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1704292 · China
Last close
$23.53
Market Cap
$2.91B
52W High
$29.02
52W Low
$15.96
ADV30
1,127,960
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 108,208,000 56,903,000 -62,978,000 -46,136,000 1,023,896,000 549,658,000 460,617,000
Jun 2026 106,311,000 58,149,000 -76,489,000 -50,825,000 1,074,793,000 607,522,000 467,756,000
Mar 2026 99,611,000 61,276,000 -69,279,000 -51,016,000 1,095,737,000 651,316,000 433,756,000
Dec 2025 127,597,000 65,266,000 -68,264,000 -50,409,000 1,172,384,000 679,573,000 456,884,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-159,208,000
Investing CF
$-47,682,000
Financing CF
$37,900,000
CapEx
$-37,954,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.90
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,776,597,000
Inventory
$85,292,000
Receivables
$75,397,000
ST Investments
$10,000,000
EBIT TTM
$-196,605,000
Pretax Income TTM
$-202,767,000
Interest Exp TTM
$6,162,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$449,614,016
EBITDA
$-248,168,000
Free Cash Flow
$-83,963,752
Enterprise Value
$2,196,723,968
Total Cash
$617,521,984
Total Debt
$254,576,000
Shares Out
123,772,253
Trailing EPS
$-1.80
Book Value
$6.47
ROE
-26.9%
ROA
-14.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 460,156,000 -223,572,000 -175,537,000 1,172,384,000 456,884,000 715,500,000 -150,789,000
Dec 2024 398,988,000 -273,947,000 -257,103,000 1,185,753,000 344,855,000 840,898,000 -214,869,000
Dec 2023 266,719,000 -374,140,000 -334,620,000 1,036,295,000 240,177,000 796,118,000 -198,178,000
Dec 2022 215,040,000 -392,886,000 -443,286,000 1,220,140,000 174,545,000 1,045,595,000 -367,642,000

TTM Snapshot

Revenues TTM
$449,614,000
NetIncome TTM
$-188,213,000
OpCashFlow TTM
—
Assets (Latest)
$1,074,793,000
Forward EPS
$-2.05

Peers — same industry

TickerNameMarket CapLastDaily %
DYN Dyne Therapeutics, Inc. $3.00B $16.02 —
TLX Telix Pharmaceuticals Ltd $3.01B $8.85 —
XERS Xeris Biopharma Holdings, Inc. $3.07B $16.80 —
BGM BGM Group Ltd. $3.09B $8.13 —
LEGN Legend Biotech Corp $3.13B $16.11 —

News headlines (Yahoo Finance, 1h cache)

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
2026-11-14 05:38 · Yahoo
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
2026-11-14 03:26 · Yahoo
Zai Lab Announces Participation in Investor Conferences in November 2026
2026-11-13 21:35 · Yahoo
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
2026-11-13 18:02 · Yahoo
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Li
2026-11-13 12:00 · Yahoo
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
2026-11-10 13:55 · Yahoo
Why Zai Lab Stock Is Up 12.7% And What's Next
2026-11-07 22:13 · Yahoo
Zai Lab (ZLAB) Draws Fresh Optimism, Is The Stock Still 24% Undervalued?
2026-11-07 08:15 · Yahoo
Zai Lab Ltd (ZLAB) Q3 2026 Earnings Call Highlights: Stabilizing China Business, Breakthrough ...
2026-11-07 05:07 · Yahoo
Zai Lab Q3 Earnings Call Highlights
2026-11-07 00:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.